Stephan Jackman
Known title: Chief Executive OfficerCIK: 0001864257
Stephan Jackman's purchase track record
Stephan Jackman has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/28/2023 | ALZN | $20K | -13.4% | -68.6% | -1.3% |
| 9/19/2022 | ALZN | $10K | -37.4% | -72.2% | +1.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ALZN | ▲ Buy | Open Market | 37,000 | $20K | 4/28/2023 | View on chart |
| ALZN | ▲ Buy | Open Market | 8,500 | $10K | 9/19/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Alzamend Neuro (ALZN) Receives Analyst Upgrade
Alzamend Neuro received an upgrade to a buy rating from an analyst. This move aligns with the firm's price target of $26.00, which is significantly higher than the stock's 52-week range of $0.84 to $2.68. The upgrade provides a positive signal for the company's outlook, although the stock currently trades near its support level.
Alzamend Neuro (ALZN) Receives Analyst Upgrade. Alzamend Neuro received an upgrade to a buy rating from an analyst. This move aligns with the firm's price target of $26.00, which is significantly higher than the stock's 52-week range of $0.84 to $2.68. The upgrade provides a positive signal for the company's outlook, although the stock currently trades near its support level.